This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
Fipexide
A dopaminergic nootropic formerly marketed in Europe (as Vigilor) that enhances dopamine D1 receptor signalling and was used for age-related cognitive decline and attention deficits.
Benefits
What is Fipexide?
Fipexide (marketed as Vigilor and Attentil) is a nootropic compound that was developed and prescribed in several European countries, particularly France and Italy, for the treatment of age-related cognitive decline, attention deficits, and memory impairment. Unlike many classical nootropics that primarily target cholinergic or glutamatergic systems, Fipexide's primary mechanism involves enhancement of dopaminergic neurotransmission, particularly through D1 receptor-mediated signalling in the prefrontal cortex. This dopaminergic emphasis gives Fipexide a distinctive pharmacological profile that addresses executive function, motivation, and attentional processing. Clinical studies conducted in the 1980s and early 1990s, including work by Bompani and Scali (1986) published in Current Medical Research and Opinion, demonstrated that Fipexide improved performance on memory tests, reaction time tasks, and measures of sustained attention in elderly patients.
Fipexide's mechanism involves increasing dopamine turnover in the prefrontal cortex and mesolimbic pathways, enhancing the availability of dopamine at post-synaptic receptors involved in cognitive processing. Additionally, research has shown that Fipexide modulates acetylcholine and serotonin systems, providing a multi-target pharmacological profile. A study by Bianchi and Musch (1989) in the International Journal of Clinical Pharmacology Research reported significant improvements in memory consolidation and retrieval in a double-blind placebo-controlled trial involving elderly outpatients. Despite these promising results, Fipexide was withdrawn from several markets in the 1990s following reports of rare but serious hepatotoxicity (liver damage), including cases of hepatic necrosis. This withdrawal has limited its clinical availability, though it remains a compound of historical interest in nootropic pharmacology and is occasionally sourced through research chemical suppliers.
- Dopamine turnover enhancement: Increases dopamine synthesis, release, and turnover in the prefrontal cortex and mesolimbic pathways, enhancing D1 receptor-mediated signalling critical for working memory and executive function
- D1 receptor signalling: Preferentially enhances D1-type dopamine receptor activation, which is strongly linked to prefrontal cortical function including working memory, cognitive flexibility, and sustained attention
- Cholinergic modulation: Secondary effects on acetylcholine release in hippocampal and cortical regions contribute to memory encoding and retrieval enhancement
- Serotonergic interaction: Modulates serotonergic neurotransmission, which may contribute to its effects on mood, anxiety, and the emotional aspects of cognitive performance
- Cerebral metabolism improvement: Enhances cerebral glucose utilisation and oxygen consumption, supporting the metabolic demands of enhanced neuronal activity
- Standard clinical dose: 100-200 mg taken two to three times daily, for a total daily dose of 200-600 mg in clinical settings
- Starting dose: 100 mg twice daily, with gradual titration upward based on response and tolerability over 1-2 weeks
- Duration of treatment: Clinical trials typically ran for 4-12 weeks, with some extending to 6 months of continuous use
- Administration: Oral tablets taken with meals to improve absorption and reduce the risk of gastrointestinal side effects
- Current availability: No longer commercially marketed in most countries; available only through research chemical suppliers, making quality and purity verification essential
- Hepatotoxicity risk: The most serious safety concern - rare but potentially severe liver damage including hepatic necrosis has been reported, leading to market withdrawal in several countries; liver function monitoring was recommended during treatment
- Liver function monitoring: Baseline and periodic liver function tests (ALT, AST, bilirubin) were recommended during clinical use; treatment should be discontinued if liver enzymes exceed 3x the upper limit of normal
- Common side effects: Gastrointestinal complaints (nausea, abdominal discomfort), headache, insomnia, and restlessness were the most frequently reported adverse effects in clinical trials
- Dopaminergic side effects: Excessive dopamine stimulation may cause agitation, anxiety, insomnia, or in rare cases psychotic symptoms in susceptible individuals
- Drug interactions: May interact with MAO inhibitors, dopamine agonists, antipsychotics, and other dopaminergic medications; concurrent use with hepatotoxic drugs should be avoided
Natural Sources & Forms
- Bompani and Scali (1986): "Fipexide, an effective cognition activator in the elderly: a placebo-controlled double-blind clinical trial" published in Current Medical Research and Opinion
- Bianchi and Musch (1989): Double-blind placebo-controlled study of Fipexide in elderly outpatients with cognitive impairment, published in the International Journal of Clinical Pharmacology Research
- Garattini and Bhatt (1991): Review of Fipexide's pharmacological profile and clinical evidence in the context of dopaminergic nootropics
- European drug safety reports: Pharmacovigilance reports documenting the hepatotoxicity cases that led to Fipexide's withdrawal from European markets in the 1990s
- Pepeu and Spignoli (1989): "Nootropic drugs and brain cholinergic mechanisms" in Progress in Neuro-Psychopharmacology and Biological Psychiatry, reviewing Fipexide among other cognitive enhancers
Frequently Asked Questions
A dopaminergic nootropic formerly marketed in Europe (as Vigilor) that enhances dopamine D1 receptor signalling and was used for age-related cognitive decline and attention deficits.
The key benefits of Fipexide include: Cognitive Enhancement, Energy, Focus, Memory, Mood, Motivation.
Dopamine turnover enhancement: Increases dopamine synthesis, release, and turnover in the prefrontal cortex and mesolimbic pathways, enhancing D1 receptor-mediated signalling critical for working memory and executive function D1 receptor signalling: Preferentially enhances D1-type dopamine receptor activation, which is strongly linked to prefrontal cortical function including working memory, cognitive flexibility, and sustained attention Cholinergic modulation: Secondary effects on acetylcholine release in hippocampal and cortical regions contribute to memory encoding and retrieval enhancement Serotonergic interaction: Modulates serotonergic neurotransmission, which may contribute to its effects on mood, anxiety, and the emotional aspects of cognitive performance Cerebral metabolism improvement: Enhances cerebral glucose utilisation and oxygen consumption, supporting the metabolic demands of enhanced neuronal activity
Standard clinical dose: 100-200 mg taken two to three times daily, for a total daily dose of 200-600 mg in clinical settings Starting dose: 100 mg twice daily, with gradual titration upward based on response and tolerability over 1-2 weeks Duration of treatment: Clinical trials typically ran for 4-12 weeks, with some extending to 6 months of continuous use Administration: Oral tablets taken with meals to improve absorption and reduce the risk of gastrointestinal side effects Current availability: No longer commercially marketed in most countries; available only through research chemical suppliers, making quality and purity verification essential
Hepatotoxicity risk: The most serious safety concern - rare but potentially severe liver damage including hepatic necrosis has been reported, leading to market withdrawal in several countries; liver function monitoring was recommended during treatment Liver function monitoring: Baseline and periodic liver function tests (ALT, AST, bilirubin) were recommended during clinical use; treatment should be discontinued if liver enzymes exceed 3x the upper limit of normal Common side effects: Gastrointestinal complaints (nausea, abdominal discomfort), headache, insomnia, and restlessness were the most frequently reported adverse effects in clinical trials Dopaminergic side effects: Excessive dopamine stimulation may cause agitation, anxiety, insomnia, or in rare cases psychotic symptoms in susceptible individuals Drug interactions: May interact with MAO inhibitors, dopamine agonists, antipsychotics, and other dopaminergic medications; concurrent use with hepatotoxic drugs should be avoided
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!